GALT Stock Forecast: Galectin Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Galectin Therapeutics, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 82 of 100 as at 21 Nov 2026 — inside the top quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Galectin Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (81): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
GALT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GALT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $11 |
| 17 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2025 | HC Wainwright & Co. | Assumes | Buy | $6.00 |
| 2 Apr 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 27 Dec 2024 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 May 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Apr 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Aug 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Apr 2020 | B. Riley FBR | Maintains | Buy | — |
| 3 Apr 2020 | B. Riley Securities | Maintains | Buy | — |
| 17 Mar 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Feb 2019 | B. Riley FBR | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GALT.
This page is one stock. Monday covers all of them.
GALT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
GALT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Galectin Therapeutics, Inc. returned −53.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
GALT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −71.5%
- Dividend yield
- —
Higher than 5% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Galectin Therapeutics, Inc. has a market value of $271.4M and an enterprise value of $300.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$27.8M.
Free cash flow in the twelve months to 30 June 2026: −$15.9M.
Galectin Therapeutics, Inc. employs 9 people.
Data provided by Twelve Data
GALT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at GALT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Galectin Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about GALT
What is the GALT stock price forecast for 2026-2027?
The median 12-month analyst price target for Galectin Therapeutics, Inc. is $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GALT stock a buy right now?
Of the 1 analyst covering Galectin Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Galectin Therapeutics, Inc. 82 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GALT?
As at 21 Nov 2026, Galectin Therapeutics, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (81 of 100).
Will GALT stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $11, and Ticker Nerd's factor model ranks Galectin Therapeutics, Inc. 82 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GALT stock forecast for 2030?
No analyst covering Galectin Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GALT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $11 over the next 12 months.
How has GALT stock performed over the past year?
Galectin Therapeutics, Inc. returned -53.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Galectin Therapeutics, Inc. do?
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic disease, cancer, and selected other chronic conditions. Galectin Therapeutics uses a carbohydrate-based approach centered on galectin science, targeting galectin proteins that play key roles in inflammation, fibrosis, and malignancy.
About Galectin Therapeutics, Inc.
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic disease, cancer, and selected other chronic conditions. Galectin Therapeutics uses a carbohydrate-based approach centered on galectin science, targeting galectin proteins that play key roles in inflammation, fibrosis, and malignancy. Its lead product candidate, belapectin, is a galectin-3 inhibitor being studied in programs related to metabolic dysfunction-associated steatohepatitis, liver fibrosis, cirrhosis, and portal hypertension. The company also supports research into additional galectin-related treatments, including oral small-molecule inhibitors through collaborative efforts. Galectin Therapeutics is based in Norcross, Georgia, and operates within the biotechnology sector, where it focuses on discovery and development rather than commercial-scale product sales.
CEO Mr. Joel Lewis CPA · 9 employees · United States · https://galectintherapeutics.com